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To assess the safety and efficacy of epigallocatechin-3-gallate (EGCG) add-on to glatiramer
acetate (GA) in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods
We enrolled patients with RRMS (aged 18–60 years, Expanded Disability Status Scale [EDSS]
score 0–6.5), receiving stable GA treatment in a multicenter, prospective, double-blind, phase
II, randomized controlled trial. Participants received up to 800 mg oral EGCG daily over a
period of 18 months. The primary outcome was the proportion of patients without new
hyperintense lesions on T2-weighted (T2w) brain MRI within 18 months. Secondary end
points included additional MRI and clinical parameters. Immunologic effects of EGCG were
investigated in exploratory experiments.
Results
A total of 122 patients on GA were randomly assigned to EGCG treatment (n = 62) or placebo
(n = 60). We could not demonstrate a difference between groups after 18 months for the
primary outcome or other radiologic (T2w lesion volume, T1w hypointense lesion number or
volume, number of cumulative contrast-enhancing lesions, percent brain volume change), or
clinical (EDSS, MS functional composite, and annualized relapse rate) parameter. EGCG
treatment did not affect immune response to GA. Pharmacologic analysis revealed wide ranging
EGCG plasma levels. The treatment was well tolerated with a similar incidence of mostly mild
adverse events similar in both groups.
Conclusion
In RRMS, oral EGCG add-on to GAwas not superior to placebo in influencingMRI and clinical
disease activity over 18 months. The treatment was safe at a daily dosage up to 800 mg EGCG.
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Classification of Evidence
This study provides Class II evidence that for patients with RRMS, EGCG added to GA did not significantly affect the
development of new hyperintense lesions on T2-weighted brain MRI.
Trial Registration Information
Clinical trial registration number: NCT00525668.
Multiple sclerosis (MS) is characterized by autoimmune in-
flammatory and neurodegenerative pathology of the CNS
causing pronounced neurologic disability in younger adults.1,2 In
recent years, several immunomodulatory drugs for the treatment
of relapsing-remitting MS (RRMS) have been approved tar-
geting mainly the inflammatory processes of this disease.3,4
However, the development of drugs that are capable of halting or
decelerating the neurodegenerative aspects, which are prevalent
from the earliest disease stages, is an unmet clinical need.5
Consumption of green tea is considered to have a preventive
impact on various inflammatory and neurodegenerative as
well as other diseases.6,7 The most relevant compound in this
regard is the polyphenol epigallocatechin gallate (EGCG),
comprising 50–80% of the total catechins in green tea.8
In experimental autoimmune encephalomyelitis (EAE)—an
animal model mimicking aspects of MS—EGCG exerts anti-
inflammatory properties via downregulation of NF-κB in T cells
and has neuroprotective capacities by blocking the formation of
neurotoxic reactive oxygen species in neurons.9 In thismodel, oral
EGCG significantly reduced clinical disease severity as well as
CNS inflammation and neuroaxonal damage, both as preventive
and therapeutic treatment.9,10 Moreover, in EAE, concomitant
application of EGCG and glatiramer acetate (GA) revealed
synergistic effects in vitro and in vivo.11
Against this background, we investigated the effect of oral
EGCG given as add-on to GA therapy over a period of 18
months on radiologic and clinical disease activity as well as
safety and tolerability in patients with RRMS.
Methods
Primary Research Question
We performed a prospective, double-blind, parallel-group, ran-
domized controlled trial in patients with RRMS, at 9 sites in
Germany (including general hospitals and academic medical
centers) recruiting fromAugust 2007 toMay 2011 to evaluate the
question whether oral application of up to 800 mg EGCG re-
duces the development of new hyperintense lesions on T2-
weighted (T2w) brain MRI in patients with RRMS on stable
treatment with GA 20 mg. This study provides Class II evidence
because less than 80%of randomized patients completed the trial.
Study Design and Participants
For details on the study conduct, refer to the study protocol in
the online supplement. Eligibility criteria comprised fulfillment
of the 2005McDonald criteria for RRMS,12 age between 18 and
60 years, an Expanded Disability Status Scale (EDSS)13 score of
0–6.5, and a stable treatment with GA 20 mg daily sub-
cutaneously for at least 6months. A relapse-free period of at least
30 days before randomization was mandatory. Key exclusion
criteria were any progressive forms of MS, major systemic dis-
ease, clinically relevant predefined laboratory abnormalities, and
intake of any potentially hepatotoxic medication as well as cy-
tochrome P450 3A4–inhibiting or –inducing drugs. Additional
consumption of green tea or GTE was prohibited.
Because of lacking human data, sample size calculation was based
on articles by Aktas et al.9 and Zhao et al.14 Proportions of 45%
for EGCG and 16% for placebo were assumed for the primary
end point (patients without new T2w lesions after 18 months),
leading to 92 patients in total (2-sided type 1 error = 5%, power =
80%). Because of uncertainty in the preconditions of the sample
size calculation, an internal pilot study15 was integrated into the
study. This design allows for a (blinded) recalculation of sample
sizewithout affecting the type I error.16 The planned recalculation
after the inclusion of 50 participants resulted in a sample size of
126 patients in total, assuming a prior difference of 0.20 between
proportions. This sample size was confirmed by a second internal
blinded recalculation after inclusion of 80 individuals.
Standard Protocol Approvals, Registrations,
and Patient Consents
The study was approved by the local ethics committees and by
the German Federal Institute for Drugs and Medical Devices
Glossary
AE = adverse event; CEL = contrast-enhancing lesion; EAE = experimental autoimmune encephalomyelitis; ECCG =
epigallocatechin-3-gallate;EDSS= ExpandedDisability Status Scale;GA= glatiramer acetate; ITT= intention to treat;MSFC =MS
Functional Composite;NK = natural killer;PASAT= PacedAuditory Serial AdditionTest;PBMC= peripheral bloodmononuclear
cell; PBVC = percent brain volume change; PP = per protocol; RRMS = relapsing-remitting MS; SAE = serious adverse event.
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(BfArM). This trial is registered with EudraCT (Nr. 2006-
006323-39) and clinicaltrials.gov (NCT00525668). It was
conducted strictly following the study protocol, the ap-
plicable German laws (Arzneimittelgesetz, 14. Novelle
2005), the Harmonized Tripartite Guideline for Good
Clinical Practise (ICH-GCP), and the principles of the
Declaration of Helsinki in its applicable version. Every
participant provided written informed consent before
enrollment.
Data Availability Statement
As far as permitted according to data protection requirements
and consent provided by the participants, original data are
available from the corresponding author on request from any
qualified investigator within 5 years after publication.
Randomization and Masking
Patients were randomly (1:1) assigned to receive as add-on to
GA after a dosing phase of 4 months per day either 800 mg
capsules of Sunphenon® (GTE containing >90% EGCG,
product of Taiyo International, taiyointernational.com) or
capsules of placebo, which had identical appearance.
To account for potential baseline imbalances, patients were
stratified before randomization for sex (female/male) and
T2w lesion number at screening (≤15 or >15 T2w lesions). A
separate block randomization list was generated by the in-
dependent pharmacy, which distributed the screened study
participants to the treatment groups.
Patients and all staff remained masked for treatment allo-
cation during the entire study. Tominimize the risk of biased
clinical examinations by patients reporting adverse events
(AE), an independent examining physician restricted to
performing the neurologic examination rated EDSS only.
Procedures
Standardized neurologic assessments including the EDSS13 and
Multiple Sclerosis Functional Composite (MSFC)17 with its
subtests 9-Hole Peg Test, Timed 25-Foot Walk Test, and Paced
Auditory Serial Addition Test (PASAT) were performed by an
especially trained and neurostatus-certified examiner at screening
(which was at most 1 week before randomization), then every 3
months until the end of the study at month 18, and at every
unscheduled visit when a relapse was suspected. A relapse was
defined as any new or reoccurring neurologic symptoms in the
absence of fever or infections, lasting for at least 24 hours, sep-
arated by at least 30 days from the onset of a previous relapse,
and confirmed by the independent EDSS rater. For safety
monitoring, regular medical examinations und laboratory ex-
aminations (blood count, liver enzymes, electrolytes, creatinine,
C-reactive protein, blood glucose, and coagulation) were
scheduled every 3 months and in short-term follow-up in case of
pathologic results.
MRI was performed at screening and thereafter every 3
months until the end of the study at month 18. For all study
sites, MRI measurements were performed at a single cen-
tral facility (leading study site Charité) ensuring identical
and constant acquisition conditions on a 1.5 T MRI (Sie-
mens Sonata, Siemens Medical Systems, Erlangen,
Germany).
To investigate potential immunologic effects of EGCG
treatment, we analyzed the frequencies and activation status
of T cells (CD4+ and CD8+), B cells, monocytes, and natural
killer (NK) cells by flow cytometry analysis using EDTA
whole blood samples from a randomly selected subgroup of
35 study participants (20 EGCG and 15 placebo). Further-
more, to assess the specific proliferative response to GA, pe-
ripheral blood mononuclear cells (PBMCs) were isolated
from patients’ whole blood (n = 40 EGCG group; n = 39
placebo group including the 35 patients of the immunologic
substudy).
To measure EGCG plasma levels, biosamples were acquired
at a time point after overnight fasting and before intake of the
first dose of study medication (200 mg EGCG or placebo
capsule) as well as 2 hours later after a standardized breakfast.
Plasma concentrations of EGCG were determined as pre-
viously described.18
Outcomes
The primary outcome was the proportion of patients
without new hyperintense T2w MRI lesions within 18
months. Secondary MRI outcomes were number and vol-
ume of T2w hyperintense lesions, number and volume of
T1w hypointense lesions (black holes), number of cumu-
lative contrast-enhancing lesions (CELs), and brain atro-
phy quantified by percent brain volume change (PBVC).
Secondary clinical outcome measurements were disability
progression measured by EDSS and MSFC as well as an-
nualized relapse rate. Immunologic effects of EGCG were
assessed in exploratory experiments.
Statistical Analysis
An intention-to-treat (ITT) approachwas planned as the primary
analysis. In addition, a per-protocol (PP) analysis was performed,
omitting patients withmajor protocol violations, i.e., who stopped
treatment due to adverse reaction or who disregarded study
procedures, defined asmissingmore than 2 scheduled study visits
or intake of less than 90% of the study medication.
Results are expressed as arithmetic mean ± SD, median
(range), or frequencies (%). The primary end point was
assessed using the Fisher exact test. Secondary end points
were tested for differences between groups by using the
nonparametric (exact) Mann-Whitney test for independent
groups. Differences in categorical variables were tested by the
Fisher exact test.
Differences between the EGCG and placebo groups for the
entire time course were assessed using nonparametric multi-
variate variance and covariance analyses of all longitudinal
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data in a two-factorial design.19 A p value <0.05 was consid-
ered statistically significant. All tests of secondary end points
were conducted as exploratory data analysis. Therefore, no
adjustments for multiple testing were made. Numerical cal-
culations were performed with IBM SPSS Statistics for Win-
dows, version 21 (IBM Corp., Armonk, NY), StatXact 6
(CYTEL Software Corp., Cambridge, MA), and SAS, version
9.2 (SAS Institute, Inc., Cary, NC).
Results
One hundred fifty-eight patients were screened for eligibility,
122 of whom were enrolled in the study (figure 1). Partici-
pants were randomly assigned to receive EGCG (n = 62) or
placebo (n = 60) as add-on to immunomodulatory therapy
with GA. All included patients were of Caucasian ethnicity.
The 2 groups did not differ regarding baseline variables
(table 1).
Ultimately, 17 patients in the EGCG group and 12 patients in
the placebo group did not complete the study (figure 1). This
was mainly due to personal reasons (such as relocation or the
desire to become pregnant), change from GA to other
disease-modifying therapy, or noncompliance of study rules
(e.g., missing more than 2 visits or breaking the blinding by
having the study medication analyzed by a third party). One
patient in each group discontinued due to stomach and di-
gestion complaints. In the EGCG group, 1 participant had to
stop study medication because of elevated liver enzymes
higher than threefold the upper limit of normal; elevated
values normalized thereafter. Of the patients completing the
full 18 months of study medication, 33 patients (68.8%) on
placebo and 37 patients (82.2%) on EGCG had a compliance
Figure 1 Trial Flowchart
ITT = intention to treat; PP = per protocol.
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of at least 90% regarding intake of study medication (number
of taken capsules as assessed by the drug count at study visits).
The results of the ITT analyses for the MRI outcome pa-
rameters are summarized in table 2. Regarding the primary
end point, we observed no significant difference in the pro-
portion of patients without new T2w hyperintense lesions
between EGCG- and placebo-treated patients at month 18.
Regarding secondary outcomes, the number of T2w lesions as
well as the number of T1w hypointense lesions (table 2)
increased irrespective of EGCG or placebo group during the
study period as did the volume of T2w hyperintense and T1w
hypointense lesions (figure 2 and table 2). Neither parameter
revealed significant differences between the study groups
(table 2).
Longitudinal analysis of the entire time course19 including all
available time points (0, 6, 12, 15, and 18 months) adjusted
for values at baseline also did not show a significant difference
in MRI parameters between the EGCG and placebo groups
(data not shown). Both groups developed a similar number of
CELs during the study.
Furthermore, we could not detect a difference between the 2
study groups in PBVC, a measure of whole-brain atrophy,
over the 18-month period of the trial (table 2).
With regard to clinical end points (table 3), no differences
were observed in EDSS or MSFC between the EGCG and
placebo groups, neither in regard to change from baseline to
month 18 nor in longitudinal EDSS analysis of the entire
study course adjusted for values at baseline.
The results of the PP analyses (n = 70) concerning primary as
well as all secondary outcome parameters did not differ in
their statistical significance from those of the ITT analyses
(data not shown).
The analysis of subgroups enables a differentiated view. In the
group of participants who did not suffer a relapse 12 months
before study inclusion, the rate of patients who did not de-
velop new T2w lesions was higher in the group with the active
ingredient (EGCG 12/21, placebo 5/19, p = 0.062). This
was also the case in the group of participants with 15
and lower T2w lesions at baseline (EGCG 10/13, placebo
3/9, p = 0.079) and surprisingly in the subgroup of patients
who developed T2w lesion volume increase during the study
(EGCG 10/38, placebo 3/35, p = 0.067). No statistically
significant difference in the rate of newly developed T2w
lesions could be demonstrated in the subgroup with EDSS 3
and lower (EGCG 13/36, placebo 11/39, p = 0.621) and in
the subgroup of patients with Gd-positive lesions in the
course of the study (EGCG 3/19, placebo 3/11, p = 0.641).





(n = 60) p Value
Age (y) 39 (9.4)1 42 (8.0)c 0.060e
Women 41 (67%) 40 (69%) 1.000f
Relapse in past 12 months 32 (52%) 36 (60%) 0.368f
EDSS 2.0 (0–6.0)d 2.0 (0–6.0)d 0.733e
Time since first MS symptoms (y) 9.8 (7.0)c 8.9 (6.4)c 0.544e
Time since MS diagnosis (y) 6.1 (4.7)c 5.4 (4.4)c 0.387e
Duration of treatment with GA (y) 3.1 (2.9)c 2.6 (2.5)c 0.190e
Multiple Sclerosis Functional Composite (z-score)a 0.083 (0.684)c 0.147 (0.675)c 0.594e
Paced Auditory Serial Addition Testa 46.8 (12.4)c 49.4 (10.7)c 0.223e
Timed 25-Foot Walk Test average speed (s) 5.1 (1.8)c 4.9 (1.9)c 0.307e
9-Hole Peg Test average speed (s) 20.7 (4.3)c 21.5 (5.6)c 0.884e
T2w lesion volume (mm3)b 5,239 (8,904)c 4,401 (6,034)c 0.792e
T2w lesion countb 36 (33)c 38 (28)c 0.443e
T1w hypointense lesion volume (mm3)b 1,758 (2,557)c 2,240 (4,171)c 0.331e
T1w hypointense lesion countb 7 (6)c 8 (6)c 0.941e
Abbreviations: EGCG = epigallocatechin-3-gallate; EDSS = Expanded Disability Status Scale; GA = glatiramer acetate.
Data are cmean (SD), number (%), or dmedian (range). e(exact) Mann-Whitney test, fFisher exact test.
a Data available for 61 patients in the EGCG group and 59 patients in the placebo group.
b Data available for 54 patients in the EGCG group and 52 in the placebo group.
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The analysis of the frequencies of the main immune cell
populations (numbers of circulating T cells, B cells, mono-
cytes, or NK cells) in a subgroup of 20 EGCG-treated and 15
placebo-treated patients revealed that the treatment with
EGCG did not alter the overall immune status of the patients
(data not shown). The in vitro examination of the T-cell
response to different concentrations of GA using PBMC from
40 EGCG and 39 placebo-treated patients indicated that
treatment with EGCG did not interfere with the overall T-cell
response of the patients to GA. Though, EGCG treatment
had a tendency to diminish the in vitro response to high GA
concentrations at 2 mg/mL (p = 0.099, data not shown). This
concentration is far higher than the serum level in humans
under regular treatment with GA.
Of the 60 participants in the placebo group, 58 (97%) expe-
rienced 1 or more AEs, with 8 (13%) having a serious adverse
event (SAE). In the EGCG group, 60 of the 62 participants
(97%) had at least 1 AE, 6 (10%) of which were considered
serious (see table e-1, links.lww.com/NXI/A458). None of
the SAEs were considered related to the study drug. All oc-
curred due to hospitalization of study participants for various
reasons. The incidence of SAE and AE was similar in both
study groups. The most common AEs were infections of the
upper respiratory, gastrointestinal, and urinary tracts. One
placebo-treated and 1 EGCG-treated patient stopped intake
of study medication because of gastrointestinal complaints. As
1 patient of the EGCG group had to be withdrawn due to
elevated liver enzymes, we performed a comparison of liver
enzyme levels between our study groups. This revealed no
significant differences (data not shown). In plasma from pa-
tients on placebo, EGCGwas not detectable at any time point.
In 41 patients on EGCG, 2 hours after ingestion of a stan-
dardized breakfast and the morning dose of 200 mg Sun-
phenon, EGCG plasma levels ranging from 20.21 to 331.66
ng/mL were measured. If the data set is divided into 2 groups
at the median of the EGCG level, the number of new T2w
lesions is less in the group with higher EGCG levels compared
with the group below the median. But the numbers are too
small for statistical significance.
Discussion
Our randomized, placebo-controlled multicenter study failed
to show an effect of oral EGCG on MRI or clinical disease
markers in patients with RRMS on stable immunomodulatory
treatment with GA.
In line with other polyphenols, experimental data had pre-
viously demonstrated that orally administered EGCG re-
duced disease severity when given at initiation or after the
onset of experimental neuroinflammation and exerted both
anti-inflammatory and neuroprotective effects, also in com-
bination with GA.9,11 Among the potential mechanisms of
action of EGCG are antioxidant properties and an impact on
several signal transduction pathways, including growth
factor–mediated pathways, the mitogen-activated protein
kinase–dependent, and ubiquitin/proteasome degradation
pathways. These data in conjunction with EGCG’s presumed
mode of action together with the finding that the conven-
tional form of MS typical for Western countries is much less
prevalent in Asian countries with high green tea consumption
like Japan20 encouraged us to conduct this randomized
placebo-controlled add-on trial.
Only a few clinical studies with patients with cancer admin-
istering high-dose EGCG or GTE had been reported before
planning of our trial.21,22 For the selection of the maximum
daily dose of EGCG, we had to rely on pharmacokinetic and
tolerability studies in healthy subjects with short-time intakes
only (maximum weeks) of doses from 800 to 1,000 mg
EGCG/GTE per day.23–25 Plasma elimination half-life of
Table 2 MRI Outcome Parameters
GA + EGCG (n = 62) GA + placebo (n = 60) p Value
Proportion of patients without new T2w lesions 18 (29%) 15 (25%) 0.686f
Number of new T2w lesionsa 3.1 (6.2) 1.9 (5.1) 0.607e
Volume of new T2w lesions (mm3)a 749 (3,639) 271 (1,592) 0.499e
Number of new T1w hypointense lesionsb 0.40 (0.8) 0.5 (1.2) 0.964e
Volume of new T1w hypointense lesions (mm3)b 118 (473) 59 (610) 0.984e
Number of CELsc 0.55 (1.04) 0.38 (1.4) 0.939e
PBVCd −0.6831 (0.7565) −0.5945 (0.7675) 0.386e
Abbreviations: GA = glatiramer acetate; CEL = contrast-enhancing lesion; EGCG = epigallocatechin-3- gallate; PBVC = percent brain volume change.
Data are mean (SD), number (%). e(exact) Mann-Whitney test, fFisher exact test.
a Data available for 53 patients in the EGCG group and 51 in the placebo group.
b Data available for 50 patients in the EGCG group and 51 in the placebo group.
c Data available for 42 patients in the EGCG group and 45 in the placebo group.
d Data available for 42 patients in the EGCG group and 42 in the placebo group.
6 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 3 | May 2021 Neurology.org/NN
EGCG was reported to be as long as 5.2 hours, and levels were
detectable after repeated administration of 800 mg EGCG once
daily over 10 days.25We therefore concluded that 400mg EGCG
twice daily would be sufficient to yield measurable plasma levels
even after overnight fasting. However, we have learned from our
data that plasma levels of EGCG are extremely variable between
individuals even under standardized conditions. Although a
dosage of 600 mg EGCG daily improved muscle metabolism in
patients with MS,26 oral ingestion of 400 mg EGCG twice daily
may not have been sufficient to exert biological effects in theCNS
in all patients due to insufficient plasma levels. This may be 1
potential explanation for the negative outcome of this study.
Recently, the bioavailability of orally administered EGCG was
called into question,27 which is however in contradiction to an
earlier pharmacokinetic study reporting a high absorption rate of
oral EGCG in the fasting state.25
Another putative cause for not meeting the efficacy end points
could lie in the add-on study design. A placebo-controlled
EGCG-only trial would have been considered unethical and
would not be approved by the competent authorities. Thus,
we had to choose an add-on approach to an approved im-
munomodulatory drug. For reasons of safety, we selected GA
because we considered this compound to be the least prob-
lematic in terms of potential unfavorable drug interactions, in
particular as hepatotoxicity had been discussed as a rare but
potentially severe side effect of green tea dietary supple-
ments.28 Fortunately, we did not face SAEs with our EGCG
dosing regimen and GA combination therapy. This is in
contrast to a small study with Polyphenon E (a GTE com-
pound) in MS that was prematurely terminated due to sig-
nificant hepatotoxicity.29 In our study, only 1 subject dropped
out due to elevated liver enzymes. Maybe EGCG as a pure
substance afflicts metabolic processes of the liver less than
GTE, containing several types of polyphenols and sometimes
small amounts of caffeine in addition.
Furthermore, in the study with Polyphenon E, add-on therapy
with interferon beta was permitted. Hepatotoxicity of this
drug is known and may account partially for the elevation of
liver enzymes reported in this study. Our trial was also safe
regarding other organ-specific side effects and participants
reported good overall tolerability of EGCG.
Immunologic analyses revealed no impact of EGCG on T-cell
responses to GA except when applying very high doses of GA,
suggesting that the study medication did not counteract the
beneficial effects of GA.
In our study cohort, all patients were under stable GA treatment
before administering EGCG, and only about half of the partici-
pants had suffered from a relapse during 12 months before study
inclusion. This is in strong contrast to recent studies on disease-
modifying drugs in MS,30,31 which report a mean of 1.4 relapses
in the previous 12 months, and demonstrates the notable sta-
bility of our study population. It is composed of many patients
with a more benign course of MS who had a median EDSS of
2.0 at study entry after 8–9 years of disease, making it even more
difficult to observe a therapeutic effect in such patients.
As both study groups (GA + EGCG and GA + placebo) also
hardly suffered from disease activity during the trial, the ab-
sence of disease dynamics made it impossible to detect an
effect of the intervention.
Overestimation of the treatment effect calculating the sample
size might also account for the difficulties in demonstrating
mild additive or synergistic effects of EGCG.
With the given data, the power is only 7% in the ITT pop-
ulation to detect the difference of percentages of patients
without new T2w lesions between verum and placebo at the
end of the study. This figure is very revealing: the small dif-
ference of percentages of patients without new T2w lesions
between treatment groups in our cohort (31.9% vs 39.1%) can
only be detected with 719 patients per group, assuming a
power of 80% and a type 1 error (α) of 5% (two-sided).
These numbers seem very high for a clinical trial, but they are
in the order of size of the phase III studies of the substances
teriflunomide (TEMSO n = 1,088, TOWER n = 1,169)30,32
and dimethyl fumarate (DEFINE n = 1,237, CONFIRM
n = 1,430),30,33 which are now approved for the treatment of
MS. The power considerations keep open the possibility of
exploring, with an appropriate study design, whether the
disease course of MS (at least in terms of T2 lesion load) can
Figure 2 T2w and T1w Hypointense Lesion Volumes
Mean change over time of volume (A) T2w lesion load (B) T1w hypointense
lesion. EGCG = epigallocatechin-3-gallate.
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be influenced by EGCG. Although the subgroup analyses only
showed a statistical trend because of the small number of cases
in the subgroups, it could be speculated with caution that
patients with MS without relapse activity and a low cerebral
lesion load could benefit from EGCG treatment.
Despite experimental evidence of anti-inflammatory and neu-
roprotective properties of EGCG,9 in the human setting, its
neuroprotective capacities may outweigh. There is growing ev-
idence from several case-controlled and cohort studies in North
America, Europe, and Asia that consumption of tea lowers the
risk of neurodegenerative disease like Alzheimer and Parkinson
disease.34 However, a recently published phase III controlled
clinical trial in multiple system atrophy could not reveal an as-
sociation with clinically relevant disease modification compared
with placebo,35 despite—also in this case—promising basic
science and animal experimental data.36 Also the evaluation of
PBVC—a marker for brain atrophy—in our study could not
prove an effect of EGCG on neurodegeneration within 18
months. Even with a significant extension of the study period to
36 months, no relevant effect of EGCG on the atrophy rate
could be demonstrated in progressive MS.37
Recent studies reported beneficial effects of orally applied
EGCG on cognitive functions in combination with cognitive
training in patients with Down syndrome and fragile X
syndrome.38,39 In our study, we assessed for the screening of
cognitive function the PASAT testing calculation ability, auditory
information processing speed, and flexibility. We could not reveal
a positive effect of EGCG on this secondary end point. Though,
our progressive MS study has provided suggestion that EGCG
may have a positive effect on the test performance in PASAT.37 As
cognitive decline in MS is an overwhelming and up to now un-
solved problem, the effect of EGCGon improvement of cognitive
function in MS should be investigated in a more sophisticated
approach.
EGCG at a dose of up to 800mg daily was safe and well tolerated
in patients with RRMS when given as add-on to GA over 18
months. However, no effect on MRI or clinical measures of
disease activity could be demonstrated. Possible explanations
include an underestimation of effect size in sample size calculation
and insufficient EGCG dosage. Given that recent studies repor-
ted beneficial effects on cognitive functions, further investigation
of EGCG in MS focused on these aspects may be warranted.
Future studies should use optimized dose regimens or newer
formulations of EGCG that increase bioavailability and offer an
improved safety profile, in particular with regard to liver toxicity.
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